SCHEMBL2941879

SCHEMBL2941879

COCC(CNc1ccc(S(N)(=O)=O)cc1[N+](=O)[O-])Sc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.50
PKM P14618 4/20 0.50
POLB P06746 3/20 0.50
DOT1L Q8TEK3 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
BCL2L1 Q07817 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.47
BDKRB1 P46663 1/20 0.46
KMT2A Q03164 3/20 0.46
GAA P10253 4/20 0.43
MAPK1 P28482 1/20 0.43
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4473072 0.89 BCL2L1 (0.48) MAPTPKMPOLBDOT1LTDP1
SCHEMBL2949549 0.86 BCL2L1 (0.57) MAPTPKMPOLBDOT1LTDP1
SCHEMBL6982442 0.79 BCL2L1 (0.69) BCL2L1
SCHEMBL2941626 0.79 BCL2L1 (0.69) BCL2L1
SCHEMBL2950676 0.78 BCL2L1 (0.73) MAPTPKMPOLBDOT1LTDP1
SCHEMBL23165560 0.77 MAPT (0.56) MAPTPKMPOLBDOT1LTDP1
SCHEMBL30074991 0.77 MAPT (0.56) MAPTPKMPOLBDOT1LTDP1
SCHEMBL1113832 0.76 BCL2L1 (0.64) MAPTPKMPOLBDOT1LTDP1
SCHEMBL6991148 0.76 BCL2L1 (0.57) MAPTPKMPOLBDOT1LTDP1
SCHEMBL1700307 0.76 MAPT (0.70) MAPTPKMPOLBDOT1LTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7754886-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2010-07-13 US disclosed
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2009-05-28 US disclosed
US-7504512-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2009-03-17 US disclosed
EP-1318978-B1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2006-02-08 EP disclosed
US-20040192681-A1 N-acylsulfonamide apoptosis promoters ABBVIE INC. 2004-09-30 US disclosed
US-6720338-B2 BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL ABBOTT LABORATORIES 2004-04-13 US disclosed
EP-1318978-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS Abbott Laboratories (US) 2003-06-18 EP disclosed
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters ABBVIE INC. 2002-07-04 US disclosed
US-20020055631-A1 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES 2002-05-09 US disclosed
WO-2002024636-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 MAPT 4851/4885PKM 4646/4885POLB 1110/4885
US-20020055631-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 MAPT 4830/4885PKM 4553/4885POLB 859/4885
US-20040192681-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 MAPT 4851/4885PKM 4646/4885POLB 1110/4885
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BCOR MAPT 4806/4885PKM 4415/4885POLB 605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.